Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUN 15 ... efficacy data will shortly be published demonstrating that thiarabine combined with clofarabine provides much greater antitumor activity than achieved by either agent alone. In one ...
2009 SEP 14 ... trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study ...
2009 SEP 14 ... (Nasdaq: GENZ) announced that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA's Oncologic ...
2009 JUN 15 ... significant global market presence can also accelerate the adoption of Clolar®/Evoltra® (clofarabine injection) and Mozobil® (plerixafor injection). Genzyme is introducing these drugs ...
2009 AUG 3 ... reach into new markets and is expected to help accelerate the adoption of Clolar® (clofarabine) and Mozobil. Second-quarter growth in this segment was also driven by the ...
2009 OCT 19 ... letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at ...
2009 NOV 2 ... Third-quarter growth in this segment was also driven by Clolar® (clofarabine injection) and Mozobil® (plerixafor injection). Mozobil was launched in Europe ...
2009 OCT 12 ... Campath, Fludara and Leukine® (sargramostim). Genzyme also markets Clolar ® (clofarabine injection), known as Evoltra® in Europe, and Mozobil® (plerixafor injection), ...
2009 MAY 4 ... cytarabine is a major cause of treatment failure in AML. Scientists considered clofarabine, approved by the FDA in 2004, and paired it with valproic acid (VPA), typically used to ...
2009 NOV 2 ... Current study results from the report, 'Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with ...
2009 MAY 25 ... According to a study from the United States, "The standard dose of clofarabine is 52 mg/m(2) for pediatrics and 40 mg/m(2) in adults....
2009 AUG 24 ... a higher risk of disease relapse." "Given the evidence of activity of clofarabine and cytarabine in myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), we explored ...
2009 NOV 23 ... received fludarabine/melphalan, 44 received fludarabine/busulfan, and 24 received clofarabine/melphalan in addition to alemtuzumab," scientists in the United States report. ...
2009 AUG 31 ... the treatment of cancer--amifostine, fludarabine, dacarbazine, lomustine, carmustine and clofarabine--with seven additional drugs in late stage preclinical and early clinical trials. ...
2009 JUN 22 ... have important roles in the treatment of hematologic malignancies."
"Clofarabine is a next generation nucleoside analog which is under clinical investigation. The bone ...
2009 NOV 23 ... Cytarabine and Additive in Combination with Azacitidine, Decitabine and Clofarabine Keywords: Sunesis Pharmaceuticals, Inc., Cancer, Oncology, Clinical Trial ...
2009 NOV 2 ... (Dacogen®, Eisai Inc.), have been added as low intensity treatment options and clofarabine (Clolar®, Genzyme Corporation) as intermediate intensity treatment option for ...
